🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

9+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 9 of 9 recruiting trials for “Sarcoma of cervix uteri

NARecruitingNCT07071727

Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas

🏥 The Netherlands Cancer Institute📍 6 sites📅 Started Dec 2025View details ↗
Phase 2RecruitingNCT07192068

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

👨‍⚕️ Barbara PISTILLI, Dr, Gustave Roussy, VILLEJUIF📍 4 sites📅 Started Oct 2025View details ↗
Phase 1RecruitingNCT06771219

SLV-154 Treatment of Metastatic Solid Tumors

🏥 Solve Therapeutics📍 9 sites📅 Started May 2025View details ↗
RecruitingNCT06904365

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

👨‍⚕️ Michael Waters, M.D., Ph.D., Washington University School of Medicine📍 1 site📅 Started Apr 2025View details ↗
Phase 2RecruitingNCT06580002

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

👨‍⚕️ Alexandre Chan, PharmD, MPH, Chao Family Comprehensive Cancer Center📍 1 site📅 Started Dec 2024View details ↗
NARecruitingNCT06103669

Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)

👨‍⚕️ Xiao Zhao, MD, University of California, Davis📍 1 site📅 Started Oct 2023View details ↗
RecruitingNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

👨‍⚕️ Brian Rini, MD, Vanderbilt-Ingram Cancer Center📍 17 sites📅 Started May 2022View details ↗
Phase 1, PHASE2RecruitingNCT05187338

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

👨‍⚕️ Zhenfeng Zhang, MD, PHD, Second Affiliated Hospital of Guangzhou Medical University📍 1 site📅 Started Nov 2021View details ↗
NARecruitingNCT03017573

Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)

👨‍⚕️ Edith BORCOMAN, Prof., Institut Curie📍 6 sites📅 Started Jan 2017View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →